These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 18820816)

  • 1. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
    Davidson JA; Parente EB; Gross JL
    Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
    Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
    Ahrén B
    Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
    Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incretin related agents for treatment of diabetes mellitus].
    Miyagawa J; Miuchi M; Nanba M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
    [No Abstract]   [Full Text] [Related]  

  • 11. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incretin-based therapy for treating patients with type 2 diabetes].
    Jermendy G
    Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
    Nicolucci A; Rossi MC
    Acta Biomed; 2008 Dec; 79(3):184-91. PubMed ID: 19260377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
    Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New concepts in the treatment of type 2 diabetes].
    Meier JJ; Schmidt WE; Klein HH
    Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S10-9. PubMed ID: 20824235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.